Cargando…
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrol...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516873/ https://www.ncbi.nlm.nih.gov/pubmed/28761384 http://dx.doi.org/10.2147/LCTT.S113177 |